Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960569 | 0.79 | APEX1 (0.50) | APEX1POLB | |
| SCHEMBL3430755 | 0.71 | MEN1 (0.58) | MAPTNPSR1 | |
| SCHEMBL6005632 | 0.71 | MEN1 (0.58) | MAPTNPSR1 | |
| SCHEMBL4911340 | 0.69 | HCAR2 (0.44) | MAPTLMNA | |
| SCHEMBL689564 | 0.66 | MAPT (0.53) | MAPTNPSR1POLBLMNA | |
| SCHEMBL77732 | 0.65 | MEN1 (0.63) | MAPTNPSR1 | |
| SCHEMBL27924201 | 0.62 | GAA (0.38) | MAPTNPSR1POLBCYP2D6LMNA | |
| SCHEMBL15426941 | 0.62 | KDM4E (0.56) | MAPTPOLB | |
| SCHEMBL9960625 | 0.62 | MAPT (0.39) | MAPTNPSR1POLBLMNA | |
| SCHEMBL26080815 | 0.62 | MAPT (0.47) | MAPTNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388124-B2 | Ingenol-3-acylates I | LEO LABORATORIES LIMITED (IE) | 2016-07-12 | — | — | US | claimed |
| CN-103443066-A | Ingenol-3-acylates I | LEO LABORATIRIES LTD | 2013-12-11 | — | — | CN | claimed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | claimed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| US-9388124-B2 | Ingenol-3-acylates I | LEO LABORATORIES LIMITED (IE) | 2016-07-12 | — | — | US | disclosed |
| CN-103443066-A | Ingenol-3-acylates I | LEO LABORATIRIES LTD | 2013-12-11 | — | — | CN | disclosed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324600-A1 | INGENOL-3-ACYLATES I | CXCL8, MMP8, CASP8 | MAPT 4684/4885NPSR1 1517/4885APEX1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.